• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by uniQure N.V.

    6/30/25 7:36:22 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    S-8 1 qure-20250630xs8.htm S-8

    As filed with the Securities and Exchange Commission on June 30, 2025

    ​

    Registration No. 333-

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    FORM S-8

    ​

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

    ​

    UNIQURE N.V.

    (Exact Name of Registrant as Specified in its Charter)

    ​

    Netherlands

    N/A

    (State or Other Jurisdiction of Incorporation or
    Organization)

    (I.R.S. Employer Identification
    No.)

    Paasheuvelweg 25a,
    1105 BP Amsterdam, The Netherlands

    N/A

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    uniQure N.V. Amended and Restated 2014 Share Incentive Plan

    (Full Title of the Plan)

    ​

    Matthew Kapusta

    Chief Executive Officer

    1 Hartwell Place

    Lexington, MA 02421

    (Name and Address of Agent For Service)

    ​

    Tel: +1 339 970 7000

    (Telephone Number, Including Area Code, of Agent For Service)

    ​

    ​

    Copies to:

    ​

    Jeannette Potts

    Chief Legal Officer

    1 Hartwell Place

    Lexington, MA 02421

    +1 339 970 7000

    ​

    Timothy J. Corbett

    Benjamin Stein

    Morgan, Lewis & Bockius LLP

    One Federal Street

    Boston, MA 02110

    +1 617 341 7700s

    ​

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer ☐

    Accelerated filer ☒

    Non-accelerated filer ☐

    Smaller reporting company ☐

     

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    ​

    ​

    ​


    EXPLANATORY NOTE

    ​

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by uniQure N.V. (the “Registrant”) solely for the purpose of registering an additional 2,400,000 ordinary shares, par value €0.05 per share, of the Registrant (the “Ordinary Shares”) to be offered to participants under the Registrant’s Amended and Restated 2014 Share Incentive Plan, which was originally adopted at the annual general meeting of the Registrant’s shareholders on January 9, 2014 and was subsequently amended or amended and restated, as applicable, as of June 10, 2015, June 15, 2016, June 13, 2018, June 16, 2021, November 15, 2023, June 18, 2024 and June 11, 2025 (as so amended or as amended and restated to date, the “2014 Plan”).

    ​

    On April 15, 2025, an amendment to the 2014 Plan (in the form then in effect) was approved by the board of directors of the Registrant and was subsequently approved by the Registrant’s shareholders at its annual general meeting on June 11, 2025 to increase the number of Ordinary Shares reserved for issuance under the 2014 Plan by an additional 2,400,000 shares.

    ​

    The Ordinary Shares registered hereby are in addition to and of the same class as those on the Registrant’s registration statements on Form S-8 registering (i) 1,531,471 Ordinary Shares issuable under 2014 Plan previously filed with the Securities and Exchange Commission (the “Commission”) on August 6, 2014 (File No. 333-197887), (ii) 4,070,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on May 15, 2017 (File No. 333-218005), (iii) 3,000,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on June 14, 2018 (File No. 333-225629), (iv) 4,000,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on July 20, 2021 (File No. 333-258036), (v) 1,750,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on February 28, 2024 (File No. 333-277439) and (vi) 1,500,000 Ordinary Shares issuable under the 2014 Plan previously filed with the Commission on August 1, 2024 (File No. 333-281165 (collectively, the “Previous Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Previous Registration Statements and the contents incorporated by reference therein are hereby incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

    ​


    ​

    ​

    ​

    PART II

    ​

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ​

    Item 3. Incorporation of Documents by Reference.

    ​

    The following documents are incorporated herein by reference:

    ​

    (a) The Registrant’s Annual Report on Form 10-K for fiscal year ended December 31, 2024 filed with the Commission on February 27, 2025;

    ​

    (b) The Registrant’s Quarterly Reports on Form 10-Q filed with the Commission on May 9, 2025;

    ​

    (c) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 from the Registrant's Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 28, 2025;

    (d) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 8, 2025, April 16, 2025 and June 13, 2025; and

    ​

    (e) The description of the securities contained in the Registrant’s registration statement on Form 8-A (Registration No. 001-36294) filed with the Commission on January 31, 2014, under the Securities Exchange Act of 1934, as amended (the “Exchange

    Act”), including any amendment or report filed for the purpose of updating such description.

    ​

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

    ​

    Item 8. Exhibits.

    ​

    A list of exhibits filed herewith is contained in the Exhibit Index that immediately precedes the signature page hereto and is incorporated herein by reference.

    ​

    ​

    ​


    EXHIBIT INDEX

    ​

    Number

        

    Description

    5.1*

     

    Opinion of Rutgers & Posch N.V., counsel to the Registrant

    23.1*

     

    Consent of Rutgers & Posch N.V. (included in Exhibit No. 5.1)

    23.2*

     

    Consent of KPMG Accountants N.V., Independent Registered Public Accounting Firm

    24.1*

     

    Power of attorney (included on the signature pages of this Registration Statement on Form S-8)

    99.1

    ​

    Amended and Restated 2014 Share Incentive Plan of the Registrant (incorporated by reference to Exhibit No. 10.1

    to the Registrant’s Current Report on Form 8-K filed on June 13, 2025 (File No. 001-36294).

    107*

     

    Filing Fee Table

    ​

    * Filed herewith.

    ​

    ​


    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Amsterdam, the Netherlands, on June 30, 2025.

    ​

    ​

    UNIQURE N.V.

    ​

     

     

    ​

    By:

    /s/ Matthew Kapusta

    ​

     

    Matthew Kapusta

    ​

     

    Chief Executive Officer

    ​

    ​

    ​

    ​


    POWER OF ATTORNEY AND SIGNATURES

    ​

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Matthew Kapusta and Christian Klemt, and each of them, as his or her true and lawful agent, proxy and attorney-in-fact, each acting alone, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to (i) act on, sign, and file with the SEC any and all amendments (including post-effective amendments) to this registration statement together with all schedules and exhibits thereto, (ii) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (iii) act on and file any supplement to any prospectus included in this registration statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act and (iv) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his substitutes may lawfully do or cause to be done by virtue thereof.

    ​

    Pursuant to the requirements of the Securities Act, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    ​

    Signatures

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Matthew Kapusta

    ​

    Chief Executive Officer and Director

    ​

    June 30, 2025

    Matthew Kapusta

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Christian Klemt

    ​

    Chief Financial Officer

    ​

    June 30, 2025

    Christian Klemt

    ​

    (Principal Financial Officer and Principal Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Madhavan Balachandran

    ​

    Director

    ​

    June 30, 2025

    Madhavan Balachandran

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Robert Gut

    ​

    Director

    ​

    June 30, 2025

    Robert Gut

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Rachelle Jacques

    ​

    Director

    ​

    June 30, 2025

    Rachelle Jacques

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jack Kaye

    ​

    Director

    ​

    June 30, 2025

    Jack Kaye

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ David Meek

    ​

    Director

    ​

    June 30, 2025

    David Meek

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Leonard Post

    ​

    Director

    ​

    June 30, 2025

    Leonard Post

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jeremy P. Springhorn

    ​

    Director

    ​

    June 30, 2025

    Jeremy P. Springhorn

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​


    AUTHORIZED UNITED STATES REPRESENTATIVE

    ​

    Pursuant to the requirement of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of the aforementioned Registrant, has signed this Registration Statement on June 30, 2025.

    ​

    UNIQURE, INC.

    ​

     

     

    ​

    By:

    /s/ Jeannette Potts

    ​

    Name: Jeannette Potts

    ​

    Title: Chief Legal Officer

    ​

    ​


    Get the next $QURE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    More analyst ratings

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on uniQure with a new price target

      Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

      4/1/25 8:05:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure upgraded by Raymond James

      Raymond James upgraded uniQure from Outperform to Strong Buy

      12/10/24 11:36:55 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on uniQure with a new price target

      Raymond James resumed coverage of uniQure with a rating of Outperform and set a new price target of $20.00

      10/10/24 8:37:20 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    SEC Filings

    See more
    • SEC Form S-8 filed by uniQure N.V.

      S-8 - uniQure N.V. (0001590560) (Filer)

      6/30/25 7:36:22 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/13/25 5:27:13 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - uniQure N.V. (0001590560) (Filer)

      6/2/25 8:25:16 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Abi-Saab Walid sold $20,407 worth of Ordinary Shares (1,466 units at $13.92), decreasing direct ownership by 0.97% to 150,437 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      7/1/25 4:49:12 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springhorn Jeremy P. sold $30,518 worth of Ordinary Shares (2,112 units at $14.45), decreasing direct ownership by 5% to 37,694 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/24/25 6:08:11 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Post Leonard E sold $30,518 worth of Ordinary Shares (2,112 units at $14.45), decreasing direct ownership by 7% to 29,937 units (SEC Form 4)

      4 - uniQure N.V. (0001590560) (Issuer)

      6/24/25 6:03:58 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

      ~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & Diagnostics Development Symposium (ETDD) ~ LEXINGTON, Mass. and AMSTERDAM, May 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of a clinical case study of the first participant dosed in the first cohort of its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, in patients with refractory MTLE. The data are being

      5/29/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    See more
    • uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

      ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

      6/11/25 8:00:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

      LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

      6/26/23 7:11:42 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Financials

    Live finance-specific insights

    See more
    • uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

      ~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis

      6/2/25 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure to Announce First Quarter 2025 Financial Results

      LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA submission and potential commercialization, uniQure is initiating quarterly earnings calls to provide regular updates on progress and to enhance engagement with the investment community. The event will be webcast under the Events & Presentations section of uniQure's

      5/5/25 4:05:00 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

      ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~         ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company reached agreement

      12/10/24 7:05:00 AM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/14/24 12:01:42 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      11/13/24 4:05:14 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by uniQure N.V.

      SC 13G/A - uniQure N.V. (0001590560) (Subject)

      10/25/24 9:48:27 PM ET
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care